224 related articles for article (PubMed ID: 33264292)
1. Enhanced detection of cell-free DNA (cfDNA) enables its use as a reliable biomarker for diagnosis and prognosis of gastric cancer.
Bu J; Lee TH; Jeong WJ; Poellmann MJ; Mudd K; Eun HS; Liu EW; Hong S; Hyun SH
PLoS One; 2020; 15(12):e0242145. PubMed ID: 33264292
[TBL] [Abstract][Full Text] [Related]
2. Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients.
Valpione S; Gremel G; Mundra P; Middlehurst P; Galvani E; Girotti MR; Lee RJ; Garner G; Dhomen N; Lorigan PC; Marais R
Eur J Cancer; 2018 Jan; 88():1-9. PubMed ID: 29175734
[TBL] [Abstract][Full Text] [Related]
3. Liquid Biopsy in Gastric Cancer: Analysis of Somatic Cancer Tissue Mutations in Plasma Cell-Free DNA for Predicting Disease State and Patient Survival.
Varkalaite G; Forster M; Franke A; Kupcinskas J; Skieceviciene J
Clin Transl Gastroenterol; 2021 Sep; 12(9):e00403. PubMed ID: 34644276
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of cell-free DNA concentration and integrity in serum of gastric cancer patients before and after surgery.
Zhang X; Wu Z; Shen Q; Li R; Jiang X; Wu J; Li D; Wang D; Zou C; Zhong Y; Cheng X
Cell Mol Biol (Noisy-le-grand); 2019 Sep; 65(7):111-117. PubMed ID: 31880527
[TBL] [Abstract][Full Text] [Related]
5. Improving diagnostic accuracy of identifying gastric cancer patients with peritoneal metastases: tumor-guided cell-free DNA analysis of peritoneal fluid.
van der Sluis K; van Sandick JW; Vollebergh MA; van Dieren JM; Hugen N; Hartemink KJ; Veenhof AAFA; Verhoeven E; van den Berg JG; Snaebjornsson P; Noe M; van Wezel T; Boelens MC; Kodach LL
Oncogene; 2024 Jun; 43(24):1877-1882. PubMed ID: 38654110
[TBL] [Abstract][Full Text] [Related]
6. The Ratio of ssDNA to dsDNA in Circulating Cell-Free DNA Extract is a Stable Indicator for Diagnosis of Gastric Cancer.
Huang X; Zhao Q; An X; Pan J; Zhao L; Shen L; Xu Y; Yuan D
Pathol Oncol Res; 2020 Oct; 26(4):2621-2632. PubMed ID: 32632900
[TBL] [Abstract][Full Text] [Related]
7. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
[TBL] [Abstract][Full Text] [Related]
8. Cell-free DNA concentration and fragment size as a biomarker for prostate cancer.
Chen E; Cario CL; Leong L; Lopez K; Márquez CP; Chu C; Li PS; Oropeza E; Tenggara I; Cowan J; Simko JP; Chan JM; Friedlander T; Wyatt AW; Aggarwal R; Paris PL; Carroll PR; Feng F; Witte JS
Sci Rep; 2021 Mar; 11(1):5040. PubMed ID: 33658587
[TBL] [Abstract][Full Text] [Related]
9. Circulating cell-free DNA in plasma of colorectal cancer patients - A potential biomarker for tumor burden.
Bhangu JS; Taghizadeh H; Braunschmid T; Bachleitner-Hofmann T; Mannhalter C
Surg Oncol; 2017 Dec; 26(4):395-401. PubMed ID: 29113658
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review.
Cervena K; Vodicka P; Vymetalkova V
Mutat Res Rev Mutat Res; 2019; 781():100-129. PubMed ID: 31416571
[TBL] [Abstract][Full Text] [Related]
11. Multi-dimensional cell-free DNA-based liquid biopsy for sensitive early detection of gastric cancer.
Yu P; Chen P; Wu M; Ding G; Bao H; Du Y; Xu Z; Yang L; Fang J; Huang X; Lai Q; Wei J; Yan J; Yang S; He P; Wu X; Shao Y; Su D; Cheng X
Genome Med; 2024 Jun; 16(1):79. PubMed ID: 38849905
[TBL] [Abstract][Full Text] [Related]
12. Cell-Free DNA and Clinical Characteristics in Patients with Small Intestinal or Pancreatic Neuroendocrine Tumors.
Oversoe SK; Sorensen BS; Tabaksblat EM; Gronbaek H; Kelsen J
Neuroendocrinology; 2022; 112(1):43-50. PubMed ID: 33461190
[TBL] [Abstract][Full Text] [Related]
13. Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer.
Pairawan S; Hess KR; Janku F; Sanchez NS; Mills Shaw KR; Eng C; Damodaran S; Javle M; Kaseb AO; Hong DS; Subbiah V; Fu S; Fogelman DR; Raymond VM; Lanman RB; Meric-Bernstam F
Clin Cancer Res; 2020 Apr; 26(8):1924-1931. PubMed ID: 31852833
[TBL] [Abstract][Full Text] [Related]
14. Methylation status and long-fragment cell-free DNA are prognostic biomarkers for gastric cancer.
Ko K; Kananazawa Y; Yamada T; Kakinuma D; Matsuno K; Ando F; Kuriyama S; Matsuda A; Yoshida H
Cancer Med; 2021 Mar; 10(6):2003-2012. PubMed ID: 33641249
[TBL] [Abstract][Full Text] [Related]
15. Circulating cell-free DNA variables as marker of ovarian cancer patients: A pilot study.
Stamenkovic S; Cheng J; Surowy H; Burwinkel B; Gündert M
Cancer Biomark; 2020; 28(2):159-167. PubMed ID: 32176629
[TBL] [Abstract][Full Text] [Related]
16. Identification of Potential Genomic Alterations Using Pan-Cancer Cell-Free DNA Next-Generation Sequencing in Patients With Gastric Cancer.
Kim B; Kim Y; Cho JY; Lee KA
Ann Lab Med; 2024 Mar; 44(2):164-173. PubMed ID: 37903652
[TBL] [Abstract][Full Text] [Related]
17. Aberrant Telomere Length in Circulating Cell-Free DNA as Possible Blood Biomarker with High Diagnostic Performance in Endometrial Cancer.
Benati M; Montagnana M; Danese E; Mazzon M; Paviati E; Garzon S; Laganà AS; Casarin J; Giudici S; Raffaelli R; Ghezzi F; Franchi M; Lippi G
Pathol Oncol Res; 2020 Oct; 26(4):2281-2289. PubMed ID: 32462419
[TBL] [Abstract][Full Text] [Related]
18. Rapid and ultrasensitive detection of circulating human papillomavirus E7 cell-free DNA as a cervical cancer biomarker.
Rungkamoltip P; Temisak S; Piboonprai K; Japrung D; Thangsunan P; Chanpanitkitchot S; Chaowawanit W; Chandeying N; Tangjitgamol S; Iempridee T
Exp Biol Med (Maywood); 2021 Mar; 246(6):654-666. PubMed ID: 33307803
[TBL] [Abstract][Full Text] [Related]
19. Plasma cell-free DNA chromosomal instability analysis by low-pass whole-genome sequencing to monitor breast cancer relapse.
Zhou H; Wang XJ; Jiang X; Qian Z; Chen T; Hu Y; Chen ZH; Gao Y; Wang R; Ye WW; Cao WM
Breast Cancer Res Treat; 2019 Nov; 178(1):63-73. PubMed ID: 31364001
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up.
Boons G; Vandamme T; Mariën L; Lybaert W; Roeyen G; Rondou T; Papadimitriou K; Janssens K; Op de Beeck B; Simoens M; Demey W; Dero I; Van Camp G; Peeters M; Op de Beeck K
Clin Cancer Res; 2022 Jan; 28(2):338-349. PubMed ID: 34759042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
